- Home
- SEER vs ALEC Comparison
SEER vs ALEC Comparison
Compare SEER & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | ALEC |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 124.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SEER | ALEC |
|---|---|---|
| Price | $1.90 | $1.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 154.7K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,376,999.00 | ★ $69,048,000.00 |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $24.00 | $314.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.11 | ★ 12.26 |
| 52 Week Low | $1.62 | $0.87 |
| 52 Week High | $2.59 | $3.40 |
Technical Indicators
Market Signals| Indicator | SEER | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 37.51 |
| Support Level | $1.91 | $1.09 |
| Resistance Level | $2.02 | $1.39 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 31.83 | 40.00 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.